vimarsana.com
Home
Live Updates
Marvel Biosciences Corp.: Marvel Biosciences Achieves CGMP Milestone and Begins IND-Enabling Pre-Clinical Toxicology Testing of Lead Compound : comparemela.com
Marvel Biosciences Corp.: Marvel Biosciences Achieves CGMP Milestone and Begins IND-Enabling Pre-Clinical Toxicology Testing of Lead Compound
Calgary, Alberta--(Newsfile Corp. - December 8, 2021) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased
Related Keywords
Japan ,
United States ,
Hong Kong ,
Shenzhen ,
Guangdong ,
China ,
Kentucky ,
Calgary ,
Alberta ,
Canada ,
America ,
Canadian ,
Kostenloser Wertpapierhandel ,
Istradefylline Nourianz ,
Mark Williams ,
Marvel Biosciences Corp ,
Marvel Biotechnology Inc ,
Virtus Advisory Group ,
Alberta Newsfile Corp ,
Company Or Marvel ,
Regulation Services Provider ,
Venture Exchange ,
Pharmaron Inc ,
Chief Science ,
Chief Executive Officer ,
Both Istradefylline ,
Shenzhen Stock ,
Stock Code ,
North America ,
Biosciences Corp ,
Marvel ,
Iosciences ,
Orp ,
Chieves ,
Gmp ,
Milestone ,
Egins ,
Nabling ,
Linical ,
Toxicology ,
Testing ,
Head ,
Compound ,
comparemela.com © 2020. All Rights Reserved.